Menu
Contact
Individual Investors

Subscribe to email updates

Subscribe now

Financial Professionals

Subscribe to email updates, or password protected financial professional-only content
email address/username
password
New? Register Here
Forgot Password

BBH
VanEck Vectors Biotech ETF

  • Fund Description

    VanEck Vectors Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS™ US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.

  •  
      

    • Fund Ticker

      BBH

    • Exchange

      NASDAQ

    • Commencement

      12/20/2011

    • ETF Structure

      Physical

    • Administrator

      Van Eck Associates

    • Custodian

      Bank of New York Mellon

    • Index Ticker

      MVBBHTR

    • Index Rebalancing

      Quarterly

  •  
    as of 05/23/17

    • 30-Day SEC Yield1

      0.45%

    • Total Net Assets

      $659.8M

    • Number of Holdings

      26

    • Options

      Available

    • Gross Expense Ratio2

      0.40%

    • Net Expense Ratio/TER2

      0.35%

    • Distribution Frequency

      Annual

    • Next Distribution Date

      12/15/2017

  • Portfolio Composition (%)
    as of 05/23/17

    • % of Net Assets

    • Stocks

      99.92

    • Bonds

      0.00

    • Other

      0.00

    • Cash

      0.08

  • Daily HoldingsDaily Holdings (%) as of 05/23/17

    Total Holdings: 26
    Holding Name
    Ticker
    		SharesMarket Value
    (US$)    		% of Net
    Assets
    Amgen Inc
    AMGN US
    506,311
    		78,007,33611.82
    Celgene Corp
    CELG US
    612,264
    		71,824,69010.89
    Gilead Sciences Inc
    GILD US
    1,016,845
    		65,779,7039.97
    Allergan Plc
    AGN US
    239,564
    		52,862,1928.01
    Vertex Pharmaceuticals Inc
    VRTX US
    331,581
    		38,659,0295.86
    Biogen Inc
    BIIB US
    154,327
    		38,288,5295.80
    Regeneron Pharmaceuticals Inc
    REGN US
    79,993
    		36,906,3705.59
    Illumina Inc
    ILMN US
    185,566
    		32,422,0924.91
    Quintiles Ims Holdings Inc
    Q US
    385,530
    		32,307,4144.90
    Incyte Corp
    INCY US
    224,315
    		30,542,7304.63
    Biomarin Pharmaceutical Inc
    BMRN US
    326,940
    		28,888,4184.38
    Alexion Pharmaceuticals Inc
    ALXN US
    239,439
    		25,054,8973.80
    Qiagen Nv
    QGEN US
    530,328
    		17,368,2422.63
    Grifols Sa
    GRFS US
    699,021
    		14,973,0302.27
    Tesaro Inc
    TSRO US
    78,690
    		12,210,3271.85
    Charles River Laboratories Internationa
    CRL US
    128,214
    		11,618,7531.76
    United Therapeutics Corp
    UTHR US
    90,901
    		11,040,8351.67
    Alkermes Plc
    ALKS US
    189,025
    		10,908,6331.65
    Ionis Pharmaceuticals Inc
    IONS US
    221,941
    		10,018,4171.52
    Seattle Genetics Inc
    SGEN US
    148,687
    		9,912,9621.50
    Neurocrine Biosciences Inc
    NBIX US
    173,280
    		9,275,6781.41
    Alnylam Pharmaceuticals Inc
    ALNY US
    100,973
    		7,559,8491.15
    Acadia Pharmaceuticals Inc
    ACAD US
    209,822
    		5,780,5960.88
    Bluebird Bio Inc
    BLUE US
    53,275
    		4,280,6460.65
    Intercept Pharmaceuticals Inc
    ICPT US
    25,102
    		2,836,2750.43
    Other/Cash
    --
    --
    		514,3810.08
    These are not recommendations to buy or to sell any security. Securities and holdings may vary.
  • Important Disclosure

    VanEck only serves professional clients in countries where the funds are registered or where funds can be sold in accordance with local private placement rules.

    130-Day SEC Yield is calculated daily, and is a standard yield calculation developed by the Securities and Exchange Commission that allows for fairer comparisons primarily among bond funds. It is based on the most recent 30-day period. This yield figure reflects the interest earned during the period after deducting the fund's expenses for the period. It does not reflect the yield an investor would have received if they had held the fund over the last twelve months assuming the most recent NAV. In the absence of temporary expense waivers or reimbursements, the 30-Day SEC Yield for VanEck Vectors Biotech ETF would have been 0.42% on 05/23/2017.

    2Fees & Expenses for BBH are capped contractually at 0.35% until at least February 1, 2018. Cap excludes certain expenses, such as interest. TER, or Total Expense Ratio, is also referred to as "Net Expense Ratio".

    3Morningstar Ratings : If applicable, when the ETF is rated three stars or more for any given period. ©Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. 

    4IIV is an abbreviation for the intraday indicative value of an ETF's Shares (and is also known as the Indicative Optimized Portfolio Value or IOPV), and is disseminated every 15 seconds during regular trading hours. The IIV is based on the current market value of the securities and/or cash required to be deposited in exchange for a Creation Unit. The IIV does not necessarily reflect the precise composition of the current portfolio of securities held by the Fund at a particular point in time or the best possible valuation of the current portfolio. Therefore, the IIV should not be viewed as a "real-time" update of the Fund's NAV, which is computed only once a day. The Fund is not involved in, or responsible for, the calculation or dissemination of the IIV and makes no warranty as to its accuracy.

    6The S&P 500® Index consists of 500 widely held common stocks covering industrial, utility, financial and transportation sector; as an Index, it is unmanaged and is not a security in which investments can be made.

    For each fund with at least a three-year history, Morningstar calculates a Morningstar Rating based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a fund's monthly performance (including the effects of sales charges, loads, and redemption fees), placing more emphasis on downward variations and rewarding consistent performance. The top 10% of funds in each category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars and the bottom 10% receive 1 star. (Each share class is counted as a fraction of one fund within this scale and rated separately, which may cause slight variations in the distribution percentages.) The Overall Morningstar Rating for a fund is derived from a weighted average of the performance figures associated with its three-, five- and ten-year (if applicable) Morningstar Rating metrics.

    An investment in the Fund may be subject to risks which include, among others, investing in the biotechnology sector, equitiy securities, health care sector, depositary receipts, medium-capitalization companies, issuer-specific changes, market, operational, index tracking, authorized participant concentration, no guarantee of active trading market, trading issues, replication management, fund shares trading, premium/discount risk and liquidity of fund shares, non-diversified, and concentration risks, all of which may adversely affect the Fund. Medium-capitalization companies may be subject to elevated risks. The Fund's assets may be concentrated in a particular sector and may be subject to more risk than investments in a diverse group of sectors.

    Price/Book Ratio is the price of a security divided by the book value per share of the security. Price/Earnings Ratio is the price of a security divided by the earnings per share of the security.

    MVIS US Listed Biotech 25 Index is the exclusive property of MV Index Solutions GmbH (a wholly owned subsidiary of the Adviser), which has contracted with Solactive AG to maintain and calculate the Index. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards MV Index Solutions GmbH, Solactive AG has no obligation to point out errors in the Index to third parties. The VanEck Vectors Biotech ETF is not sponsored, endorsed, sold or promoted by MV Index Solutions GmbH and MV Index Solutions GmbH makes no representation regarding the advisability of investing in the Fund. 

    Index returns are not Fund returns and do not reflect any management fees or brokerage expenses. Investors can not invest directly in the Index. Returns for actual Fund investors may differ from what is shown because of differences in timing, the amount invested and fees and expenses. Index returns assume that dividends have been reinvested.

    The "Net Asset Value" (NAV) of a VanEck Vectors Exchange Traded Fund (ETF) is determined at the close of each business day, and represents the dollar value of one share of the fund; it is calculated by taking the total assets of the fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV is not necessarily the same as the ETF's intraday trading value. VanEck Vectors ETF investors should not expect to buy or sell shares at NAV.

    Fund shares are not individually redeemable and will be issued and redeemed at their NAV only through certain authorized broker-dealers in large, specified blocks of shares called "creation units" and otherwise can be bought and sold only through exchange trading. Shares may trade at a premium or discount to their NAV in the secondary market. You will incur brokerage expenses when trading Fund shares in the secondary market. Past performance is no guarantee of future results. Returns for actual Fund investments may differ from what is shown because of differences in timing, the amount invested, and fees and expenses.

    Investing involves substantial risk and high volatility, including possible loss of principal. An investor should consider the investment objective, risks, charges and expenses of the Fund carefully before investing. To obtain a prospectus and summary prospectus, which contains this and other information, call 800.826.2333 or visit  vaneck.com/etfs.  Please read the prospectus and summary prospectus carefully before investing.

    This content is published in the United States for residents of specified countries. Investors are subject to securities and tax regulations within their applicable jurisdictions that are not addressed on this content. Nothing in this content should be considered a solicitation to buy or an offer to sell shares of any investment in any jurisdiction where the offer or solicitation would be unlawful under the securities laws of such jurisdiction, nor is it intended as investment, tax, financial, or legal advice. Investors should seek such professional advice for their particular situation and jurisdiction.

Van Eck Securities Corporation, Distributor
666 Third Avenue
New York, NY 10017
800.826.2333

 



© VanEck.